SCHEMBL122645

SCHEMBL122645

CCOC(=O)[C@H](CS)NC(C)=O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.59
KDM4E B2RXH2 1/20 0.59
THRB P10828 1/20 0.59
ALOX15 P16050 1/20 0.59
NFKB1 P19838 1/20 0.59
PTGS2 P35354 1/20 0.59
THPO P40225 1/20 0.59
RECQL P46063 1/20 0.59
BLM P54132 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
CAD P27708 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
KMT2A Q03164 2/20 0.41
POLB P06746 1/20 0.41
ALDH1A1 P00352 3/20 0.41
LMNA P02545 2/20 0.39
HSD17B10 Q99714 1/20 0.39
CPB2 Q96IY4 1/20 0.39
MGAM O43451 1/20 0.38
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL122644 1.00 MAPT (0.59) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL4727586 1.00 MAPT (0.59) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL929076 0.93 KDM4E (0.52) MAPTKDM4ETHRBALOX15NFKB1
Pyruvate SCHEMBL6571338 0.93 MAPT (0.56) MAPTKDM4ETHRBALOX15NFKB1
Pyruvate SCHEMBL6573546 0.93 MAPT (0.56) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL930333 0.93 KDM4E (0.52) MAPTKDM4ETHRBALOX15NFKB1
Cysteamine SCHEMBL20768365 0.91 ALOX15 (0.50) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL9292612 0.86 KDM4E (0.44) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL9292614 0.86 KDM4E (0.44) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL4990411 0.86 CAD (0.44) MAPTKDM4ETHRBALOX15NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 437 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4626414-A1 SYNERGISTIC COMBINATIONS OF REGULATED NECROSIS INHIBITORS WITH N-ACETYLCYSTEINE Seabelife (FR) 2025-10-08 EP claimed
US-20250255843-A1 COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF Nature's Fusions, LLC 2025-08-14 US claimed
EP-4561372-A1 COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF Nature's Fusions, LLC (US) 2025-06-04 EP claimed
WO-2024215786-A2 COMPOSITIONS AND METHODS FOR IMPROVING AUTOPHAGY ACTIVITY AND INHIBITING DYSFUNCTION WARRIOR ESSENTIALS, LLC (US) 2024-10-17 WO claimed
WO-2024115793-A1 SYNERGISTIC COMBINATIONS OF REGULATED NECROSIS INHIBITORS WITH N-ACETYLCYSTEINE SEABELIFE (FR) 2024-06-06 WO claimed
CN-115557865-B Thioether-promoted cysteine-based bioconjugate method 南京工业大学 2024-05-14 CN claimed
WO-2024026124-A1 COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF PETERSON MATTHEW (US) 2024-02-01 WO claimed
CN-115557865-A Thioether-promoted cysteine-based bioconjugation method 南京工业大学 2023-01-03 CN claimed
US-20220409526-A1 COMPOUNDS AND IMPLANTS FOR TREATING OCULAR DISORDERS RETINA FOUND OF THE SOUTHWEST (US) 2022-12-29 US claimed
EP-4054553-A1 COMPOUNDS AND IMPLANTS FOR TREATING OCULAR DISORDERS Retina Foundation of the Southwest (US) 2022-09-14 EP claimed
EP-0948258-A1 BRAIN TARGETED LOW MOLECULAR WEIGHT HYDROPHOBIC ANTIOXIDANT COMPOUNDS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 1999-10-13 EP claimed
WO-1999008665-A2 USE OF THIOL COMPOUNDS IN VIRAL INACTIVATION HOFSCHNEIDER PETER (DE) 1999-02-25 WO claimed
US-5846961-A Multi-faceted method to repress reproduction of latent viruses in humans and animals HIV DIAGNOSTICS, INC. (US) 1998-12-08 US claimed
WO-1998029375-A1 BRAIN TARGETED LOW MOLECULAR WEIGHT HYDROPHOBIC ANTIOXIDANT COMPOUNDS YISSUM RESEARCH AND DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 1998-07-09 WO claimed
EP-0784471-A4 MULTI-FACETED METHOD TO REPRESS REPRODUCTION OF LATENT VIRUSES IN HUMANS AND ANIMALS DYKE KNOX VAN (US) 1997-11-19 EP claimed
US-5686436-A SUPPRESSING HUMAN IMMUNODEFICIENCY VIRUS, FELINE IMMUNODEFICIENCY VIRUS, FELINE LEUKEMIA VIRUS HIV DIAGNOSTICS, INC. (US) 1997-11-11 US claimed
EP-0784471-A2 MULTI-FACETED METHOD TO REPRESS REPRODUCTION OF LATENT VIRUSES IN HUMANS AND ANIMALS Van Dyke, Knox (US) 1997-07-23 EP claimed
WO-1996010402-A1 MULTI-FACETED METHOD TO REPRESS REPRODUCTION OF LATENT VIRUSES IN HUMANS AND ANIMALS DYKE KNOX VAN (US) 1996-04-11 WO claimed
WO-1994004129-A2 COSMETIC AND DERMATOLOGICAL SUNSCREEN COMPOSITIONS CONTAINING THIOLS AND/OR THIOL DERIVATES BEIERSDORF AG (DE) 1994-03-03 WO claimed
EP-0300100-A1 Method and compounds for reducing dermal inflammations Morgan, Lee Roy (US) 1989-01-25 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250255843-A1 COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF AHCY, MGMT, CBS MAPT 2515/4885KDM4E 2170/4885THRB 3014/4885
US-20220409526-A1 COMPOUNDS AND IMPLANTS FOR TREATING OCULAR DISORDERS PDE6C, STRA6, PDE6A MAPT 2605/4885KDM4E 3217/4885THRB 753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.